- Home
- ACCS vs KPTI Comparison
ACCS vs KPTI Comparison
Compare ACCS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- KPTI
- Stock Information
- Founded
- ACCS 1988
- KPTI 2008
- Country
- ACCS United States
- KPTI United States
- Employees
- ACCS N/A
- KPTI N/A
- Industry
- ACCS Publishing
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- ACCS Consumer Discretionary
- KPTI Health Care
- Exchange
- ACCS Nasdaq
- KPTI Nasdaq
- Market Cap
- ACCS 46.0M
- KPTI 44.5M
- IPO Year
- ACCS N/A
- KPTI 2013
- Fundamental
- Price
- ACCS $12.05
- KPTI $4.42
- Analyst Decision
- ACCS Strong Buy
- KPTI Buy
- Analyst Count
- ACCS 1
- KPTI 6
- Target Price
- ACCS $15.00
- KPTI $48.50
- AVG Volume (30 Days)
- ACCS 8.7K
- KPTI 71.5K
- Earning Date
- ACCS 08-07-2025
- KPTI 08-05-2025
- Dividend Yield
- ACCS N/A
- KPTI N/A
- EPS Growth
- ACCS N/A
- KPTI N/A
- EPS
- ACCS N/A
- KPTI N/A
- Revenue
- ACCS $22,961,000.00
- KPTI $142,126,000.00
- Revenue This Year
- ACCS $7.67
- KPTI $2.09
- Revenue Next Year
- ACCS N/A
- KPTI $12.90
- P/E Ratio
- ACCS N/A
- KPTI N/A
- Revenue Growth
- ACCS 6.92
- KPTI 1.19
- 52 Week Low
- ACCS $7.61
- KPTI $3.51
- 52 Week High
- ACCS $13.35
- KPTI $17.40
- Technical
- Relative Strength Index (RSI)
- ACCS N/A
- KPTI 44.98
- Support Level
- ACCS N/A
- KPTI $4.22
- Resistance Level
- ACCS N/A
- KPTI $4.62
- Average True Range (ATR)
- ACCS 0.00
- KPTI 0.30
- MACD
- ACCS 0.00
- KPTI 0.06
- Stochastic Oscillator
- ACCS 0.00
- KPTI 56.41
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.